首页 / 产品 / 蛋白 / 活性蛋白

Recombinant Human GFPT1 protein

  • 中文名: 谷氨酰胺果糖-6-磷酸转氨酶1(GFPT1)重组蛋白
  • 别    名: GFPT1;GFAT;GFPT;;Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1
货号: PA1000-1230
Price: ¥询价
数量:
大包装询价

产品详情

纯度>90%SDS-PAGE.
种属Human
靶点GFPT1
Uniprot NoQ06210-2
内毒素< 0.01EU/μg
表达宿主E.coli
表达区间1-681aa
氨基酸序列MCGIFAYLNYHVPRTRREILETLIKGLQRLEYRGYDSAGVGFDGGNDKDW EANACKIQLIKKKGKVKALDEEVHKQQDMDLDIEFDVHLGIAHTRWATHG EPSPVNSHPQRSDKNNEFIVIHNGIITNYKDLKKFLESKGYDFESETDTE TIAKLVKYMYDNRESQDTSFTTLVERVIQQLEGAFALVFKSVHFPGQAVG TRRGSPLLIGVRSEHKLSTDHIPILYRTGKDKKGSCNLSRVDSTTCLFPV EEKAVEYYFASDASAVIEHTNRVIFLEDDDVAAVVDGRLSIHRIKRTAGD HPGRAVQTLQMELQQIMKGNFSSFMQKEIFEQPESVVNTMRGRVNFDDYT VNLGGLKDHIKEIQRCRRLILIACGTSYHAGVATRQVLEELTELPVMVEL ASDFLDRNTPVFRDDVCFFLSQSGETADTLMGLRYCKERGALTVGITNTV GSSISRETDCGVHINAGPEIGVASTKAYTSQFVSLVMFALMMCDDRISMQ ERRKEIMLGLKRLPDLIKEVLSMDDEIQKLATELYHQKSVLIMGRGYHYA TCLEGALKIKEITYMHSEGILAGELKHGPLALVDKLMPVIMIIMRDHTYA KCQNALQQVVARQGRPVVICDKEDTETIKNTKRTIKVPHSVDCLQGILSV IPLQLLAFHLAVLRGYDVDFPRNLAKSVTVE
预测分子量103 kDa
蛋白标签His tag N-Terminus
缓冲液PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.
Reconstituted protein solution can be stored at 2-8°C for 2-7 days.
Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶Always centrifuge tubes before opening.Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是3篇关于GFPT1重组蛋白的参考文献概览:

1. **文献名称**: "Recombinant human GFPT1 expression and characterization in Escherichia coli"

**作者**: Li Y, et al.

**摘要**: 研究通过在大肠杆菌中异源表达重组人GFPT1蛋白,优化了表达条件并纯化获得高纯度蛋白。酶活性分析表明重组GFPT1具有催化谷氨酰胺转化为葡萄糖胺-6-磷酸的活性,为后续功能研究奠定基础。

2. **文献名称**: "Structural insights into GFPT1-mediated hexosamine pathway regulation"

**作者**: Zhang Q, et al.

**摘要**: 利用重组GFPT1蛋白进行X射线晶体学分析,解析其三维结构,揭示了底物结合域和变构调节位点,阐明了该酶在己糖胺通路中的调控机制及其与代谢疾病的潜在关联。

3. **文献名称**: "GFPT1 deficiency in congenital myasthenic syndrome: Functional analysis using recombinant protein models"

**作者**: Thompson R, et al.

**摘要**: 通过构建突变型GFPT1重组蛋白,验证了先天性肌无力综合征患者中GFPT1基因突变的致病性,发现突变导致酶活性显著下降,进而影响糖基化过程及神经肌肉接头功能。

(注:以上为模拟摘要,实际文献需通过数据库检索确认。)

背景信息

GFPT1 (Glutamine-Fructose-6-Phosphate Transaminase 1) is a key enzyme in the hexosamine biosynthesis pathway (HBP), a metabolic pathway that converts glucose into uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), a critical substrate for protein glycosylation. As the rate-limiting enzyme of HBP, GFPT1 catalyzes the conversion of fructose-6-phosphate and glutamine to glucosamine-6-phosphate, integrating glucose, amino acid, and nucleotide metabolism. Dysregulation of GFPT1 has been implicated in various diseases, including diabetes complications, cancer, neurodegenerative disorders, and immune dysfunctions, due to its role in modulating O-GlcNAcylation—a post-translational modification that regulates cellular signaling, stress responses, and gene expression.

Recombinant GFPT1 protein is engineered for research and therapeutic applications, typically produced using expression systems like E. coli or mammalian cell cultures. Its production enables detailed studies of enzymatic activity, structural interactions, and regulatory mechanisms. Researchers utilize recombinant GFPT1 to investigate HBP’s involvement in insulin resistance, hyperglycemia-induced tissue damage, and cancer metabolism, where elevated GFPT1 expression often correlates with disease progression. Additionally, it serves as a tool for drug discovery, aiding in the screening of inhibitors targeting GFPT1 to mitigate pathological O-GlcNAcylation.

The protein’s modular domains, including glutaminase and isomerase regions, are of particular interest for understanding substrate binding and allosteric regulation. Recent studies also explore GFPT1 splice variants and their tissue-specific functions. By providing a purified, bioactive form of GFPT1. recombinant technology accelerates both basic research and translational efforts to develop therapies for metabolic and chronic diseases linked to HBP dysregulation.

客户数据及评论

折叠内容

大包装询价

×